Word

CRESCENDO

Status

Registered

Status Code

700

Status Date

Tuesday, December 6, 2022

Serial Number

79331946

Registration Number

6915016

Registration Date

Tuesday, December 6, 2022

Mark Type

3000

Filing Date

Thursday, August 12, 2021

Published for Opposition

Tuesday, September 20, 2022

Trademark Owner History

Crescendo Biologics Limited - Original Registrant

Classifications

40 Custom manufacture of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of therapies using antibodies and antibody fragments; custom manufacture of antibody and antibody fragments, for others, for use in medical therapies, including in relation to oncology; consultancy, advice and information relating to all of the aforesaid services

5 Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; therapeutic preparations that use monoclonal antibodies, namely therapeutic pharmaceutical for treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases for use in the discovery, preclinical and clinical development of therapeutic products for medical and veterinary purposes; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases for use in oncology and therapeutic treatments in relation thereto; pharmaceutical preparations for use in oncology

1 Chemicals for use in science and industry, namely, chemicals for laboratory research purposes; chemicals for use in science and industry, namely, chemicals for use in medical research; chemicals for use in science and industry, namely, chemicals for use in oncological research; antibodies and antibody fragments for scientific and laboratory use in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; laboratory chemicals, namely, antibody reagents used in cell and tissue assays for scientific and laboratory use; biochemicals, namely, monoclonal antibodies and antibody fragments for use in medical research; biochemicals, namely, monoclonal antibodies and antibody fragments for use in oncological research; molecules primarily comprised of antibodies and antibody fragments in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for use in medical research; molecules primarily comprised of antibodies and antibody fragments in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for use in oncological research; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical development, clinical development and manufacture of therapeutic products; chemicals used in industry and science

45 Licensing of intellectual property, namely, licensing of research and development; licensing of intellectual property, namely, licensing of medical therapeutic research; licensing of intellectual property, namely, licensing of research relating to antibodies and antibody fragments; licensing of intellectual property, namely, licensing of research in relation to the formation, manufacture, medical usage and manipulation of antibodies and antibody fragments; consultancy, advice and information relating to all of the aforesaid services

31 Live animals; live mice

42 Scientific and technological services, namely, research and design in the field of chemicals, biologicals, antibodies and antibody fragments; scientific laboratory services relating to antibodies and antibody fragments; scientific and technological services, namely, provision of antibodies and antibody fragments for medical and veterinary research and development in the field of chemicals, biologicals, antibodies and antibody fragments; scientific services, namely, discovery, preclinical and clinical development of therapeutic products; scientific research for others in the field of drug discovery, preclinical and clinical development of therapeutic and diagnostic products; oncological research; engineering of antibodies and antibody fragments; research into antibodies, antibody fragments for others; research into the formation, manufacture, medical usage and manipulation of antibodies and antibody fragments for others; consultancy, advice and information relating to all of the aforesaid services

The mark consists of a design of three circles, one pink circle, one green circle and one blue circle, each having U-shaped cut-outs. The three circles are centered above the wording "CRESCENDO" in grey stylized font.
The color(s) pink, blue, green and gray is/are claimed as a feature of the mark.

Trademark Events

Oct 27, 2023

Limitation From The Ib Examined, No Action Is Needed

Aug 19, 2023

Restriction Of Holder's Right Of Disposal Received

Apr 19, 2023

Final Decision Transaction Processed By Ib

Mar 29, 2023

Final Disposition Notice Sent To Ib

Mar 28, 2023

Final Disposition Processed

Mar 6, 2023

Final Disposition Notice Created, To Be Sent To Ib

Dec 6, 2022

Notice Of Registration Confirmation Emailed

Dec 6, 2022

Registered-Principal Register

Sep 27, 2022

Notification Processed By Ib

Sep 20, 2022

Official Gazette Publication Confirmation E-Mailed

Sep 20, 2022

Published For Opposition

Sep 7, 2022

Notification Of Possible Opposition Sent To Ib

Sep 7, 2022

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Aug 31, 2022

Notification Of Notice Of Publication E-Mailed

Aug 15, 2022

Approved For Pub - Principal Register

Aug 11, 2022

Teas/Email Correspondence Entered

Aug 11, 2022

Correspondence Received In Law Office

Aug 11, 2022

Teas Response To Office Action Received

Jul 13, 2022

Refusal Processed By Ib

Jun 16, 2022

Non-Final Action Mailed - Refusal Sent To Ib

Jun 16, 2022

Refusal Processed By Mpu

May 24, 2022

Non-Final Action (Ib Refusal) Prepared For Review

May 23, 2022

Non-Final Action Written

May 13, 2022

Assigned To Examiner

Feb 2, 2022

Application Filing Receipt Mailed

Jan 29, 2022

New Application Office Supplied Data Entered

Jan 27, 2022

Sn Assigned For Sect 66a Appl From Ib